CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Joseph P Burnett Max S Wicha |
| Publication date | April 2, 2015 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |